NCT03366766View on ClinicalTrials.gov

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

December 6, 2020

Study Completion Date

February 8, 2023

Conditions
Non-Squamous Non-Small Cell Lung CarcinomaStage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CarcinomaStage IB Non-Small Cell Lung CarcinomaStage II Non-Small Cell Lung CancerStage IIA Non-Small Cell Lung CarcinomaStage IIB Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL

Nivolumab

Given IV

DRUG

Cisplatin

Given IV

DRUG

Pemetrexed Disodium

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

Trial Locations (2)

19001

Abington Hospital - Jefferson Health, Abington

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03366766 - Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | Biotech Hunter | Biotech Hunter